Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,064.00
Bid: 12,062.00
Ask: 12,064.00
Change: 14.00 (0.12%)
Spread: 2.00 (0.017%)
Open: 11,966.00
High: 12,124.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Rolls-Royce Up On Huge Emirates Order

Fri, 17th Apr 2015 10:20

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Friday.
-------
FTSE 100 WINNERS
-------
Rolls-Royce Holdings, up 1.3%. The jet engine and power turbine company confirmed it has won its largest ever order, worth USD9.2 billion, to provide engines and support services to Emirates for 50 Airbus A380 aircraft, a deal that breaks the stranglehold that a rival engine maker had on providing engines for the airline's fleet of superjumbo aircraft. Under the deal, the British company will provide Trent 900 engines and TotalCare service support to Emirates, with the engines to power 50 Airbus A380 aircraft due to enter service in 2016.

Pearson, up 1.4%. The educational and publishing group shares are higher after closing as the biggest faller on Thursday on a Wall Street Journal report Wednesday that the Los Angeles school district is to end its use of content provided by Pearson under the Common Core Technology Project.

Whitbread, up 0.6% at 5,256.63 pence. Credit Suisse lifted its price target for the hotel and coffee-shop operator to 6,200 pence from 5,300p, reiterating its Outperform recommendation.

Astrazeneca, up 0.6%. The pharmaceutical giant said the US Food and Drug Administration has granted orphan drug designation for its selumetinib treatment for uveal melanoma, and that the latest data from its ongoing trial of AZD9291 in non-small cell lung cancer shows a delay in disease progression. Separately, Deutsche Bank lifted the company's price target to 4,850 from 4,800, keeping its Hold rating.
-------
FTSE 100 LOSERS
-------
GKN, down 0.5% at 368.8p. Exane BNP downgraded the engineering group to Neutral from Outperform, with a price target of 380p.
-------
FTSE 250 WINNERS
-------
Hunting, up 5.8% at 636.00p. Goldman Sachs upgraded the energy services company to Conviction Buy from Buy, lifting its price target to 709p from 622p.

Qinetiq Group, up 4.8% at 204.5p. Barclays upgraded the defence services company to Overweight from Equal Weight, lifting its price target to 220p from 210p, while Goldman Sachs has slightly raised the company's price target to 208p from 204, reiterating its Hold recommendation.

Debenhams, up 4.3% at 88.57p, having hit a new 16-month high of 89.00p. Several brokers updated their stances on the department store. Citigroup upgraded Debenhams to Buy from Neutral, lifting its price target to 95p from 75p, while SocGen raised the company's price target to 80p from 67p, keeping its Hold rating. Meanwhile, UBS raised its price target to 90p from 85p, reiterating its Buy recommendation. The upgrades come after Debenhams reported a rise in profit for the first half of its financial year, with its shares touching a 15-month high Thursday.
-------
FTSE 250 LOSERS
-------
Indivior, down 2.0% at 208.90p. Deutsche Bank downgraded the former pharmaceutical division of Reckitt Benckiser to Hold from Buy, but lifted its price target to 212p from 180p.
-------
AIM ALL-SHARE WINNERS
-------
Applied Graphene Materials, up 16%. The speciality graphene materials provider said it has received positive preliminary results from independent performance testing conducted on graphene-reinforced polyurethane coatings using graphene it produced. The initial results demonstrate low loading levels of its graphene nanoplatelets substantially enhance the scratch resistance and ultimate tensile strength of a polyurethane clearcoat with minimal damage to transparency or colour, it said.

Zamano, up 10%. The Irish mobile payments and marketing company said it is now an approved direct carrier billing partner for Three Ireland. It said the connection covers all of Three's customers including those obtained during the recent acquisition of O2. Three represents approximately 36% of the mobile market in Ireland according to latest figures, it said.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.